Ignite Creation Date:
2025-12-24 @ 10:49 PM
Ignite Modification Date:
2025-12-31 @ 5:46 AM
Study NCT ID:
NCT01259869
Status:
COMPLETED
Last Update Posted:
2023-08-22
First Post:
2010-12-09
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Study of PX-866 in Patients With Glioblastoma Multiforme at Time of First Relapse or Progression
Sponsor:
NCIC Clinical Trials Group
Organization:
Study Overview
Official Title:
A Phase II Study of PX-866 in Patients With Glioblastoma Multiforme at Time of First Relapse or Progression
Status:
COMPLETED
Status Verified Date:
2020-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to find out whether the new drug PX-866 will slow the growth of your glioblastoma multiforme.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
True
Is an FDA AA801 Violation?: